Q/C Technologies (QCLS)
Market Price (6/3/2026): $4.1 | Market Cap: $33.0 MilSector: Information Technology | Industry: Technology Hardware, Storage & Peripherals
Q/C Technologies (QCLS)
Market Price (6/3/2026): $4.1Market Cap: $33.0 MilSector: Information TechnologyIndustry: Technology Hardware, Storage & Peripherals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -39% Megatrend and thematic driversMegatrends include Automation & Robotics, and Autonomous Technologies. Themes include Factory Automation, Machine Vision, Show more. | Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -95% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.0 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40% High stock price volatilityVol 12M is 149% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% Key risksQCLS key risks include [1] a complete dependency on a single, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -39% |
| Megatrend and thematic driversMegatrends include Automation & Robotics, and Autonomous Technologies. Themes include Factory Automation, Machine Vision, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -95% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.0 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40% |
| High stock price volatilityVol 12M is 149% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% |
| Key risksQCLS key risks include [1] a complete dependency on a single, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Q/C Technologies (QCLS) stock has gained about 10% since 2/28/2026 because of the following key factors:
1. Strategic Transition to Quantum-Class Computing and AI Inference. The company completed a significant pivot from pharmaceuticals to focus on energy-efficient blockchain, cryptocurrency infrastructure, and quantum-class laser-based computing, leveraging an exclusive license with LightSolver. This strategic shift was further solidified by the launch of its Optical Processing Unit (OPU) Initiative on March 18, 2026, aimed at developing proprietary Silicon Photonic Computing Architecture for AI Inference.
2. Significant Reduction in Quarterly Net Loss. Q/C Technologies reported a Q1 2026 net loss of $0.19 per share for the three months ended March 31, 2026. This represents a substantial 99.47% improvement in earnings per share compared to a loss of $36.00 in the same quarter of the previous year, indicating a positive trend in financial performance during its transitional phase.
Show more
Stock Movement Drivers
Fundamental Drivers
The 9.9% change in QCLS stock from 2/28/2026 to 6/2/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6022026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.73 | 4.10 | 9.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 8 | -81.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/2/2026| Return | Correlation | |
|---|---|---|
| QCLS | 9.9% | |
| Market (SPY) | 11.0% | 28.5% |
| Sector (XLK) | 43.0% | 21.4% |
Fundamental Drivers
The 14.5% change in QCLS stock from 11/30/2025 to 6/2/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6022026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.58 | 4.10 | 14.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 8 | -81.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/2/2026| Return | Correlation | |
|---|---|---|
| QCLS | 14.5% | |
| Market (SPY) | 11.8% | 22.2% |
| Sector (XLK) | 38.9% | 20.6% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2025 to 6/2/2026| Return | Correlation | |
|---|---|---|
| QCLS | ||
| Market (SPY) | 30.4% | 23.7% |
| Sector (XLK) | 72.7% | 21.2% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/2/2026| Return | Correlation | |
|---|---|---|
| QCLS | ||
| Market (SPY) | 88.9% | 23.7% |
| Sector (XLK) | 146.4% | 21.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QCLS Return | - | - | - | - | -14% | 5% | -9% |
| Peers Return | 27% | -49% | 26% | 84% | -35% | -2% | -5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| QCLS Win Rate | - | - | - | - | 25% | 50% | |
| Peers Win Rate | 55% | 25% | 59% | 56% | 35% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| QCLS Max Drawdown | - | - | - | - | - | -43% | |
| Peers Max Drawdown | -19% | -52% | -28% | -48% | -48% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: S, BGIN, BMR, VTIX, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/2/2026 (YTD)
How Low Can It Go
QCLS has limited trading history. Below is the Information Technology sector ETF (XLK) in its place.
| Event | XLK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.7% | -18.8% |
| % Gain to Breakeven | 34.5% | 23.1% |
| Time to Breakeven | 65 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -17.0% | -7.8% |
| % Gain to Breakeven | 20.4% | 8.5% |
| Time to Breakeven | 92 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.0% | -9.5% |
| % Gain to Breakeven | 11.2% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -33.1% | -24.5% |
| % Gain to Breakeven | 49.5% | 32.4% |
| Time to Breakeven | 246 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.2% | -33.7% |
| % Gain to Breakeven | 45.2% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.8% | -19.2% |
| % Gain to Breakeven | 31.2% | 23.8% |
| Time to Breakeven | 100 days | 105 days |
In The Past
State Street Technology Select Sector SPDR ETF's stock fell -25.7% during the 2025 US Tariff Shock. Such a loss loss requires a 34.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
QCLS has limited trading history. Below is the Information Technology sector ETF (XLK) in its place.
| Event | XLK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -25.7% | -18.8% |
| % Gain to Breakeven | 34.5% | 23.1% |
| Time to Breakeven | 65 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -33.1% | -24.5% |
| % Gain to Breakeven | 49.5% | 32.4% |
| Time to Breakeven | 246 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.2% | -33.7% |
| % Gain to Breakeven | 45.2% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.8% | -19.2% |
| % Gain to Breakeven | 31.2% | 23.8% |
| Time to Breakeven | 100 days | 105 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -51.5% | -53.4% |
| % Gain to Breakeven | 106.2% | 114.4% |
| Time to Breakeven | 797 days | 1085 days |
In The Past
State Street Technology Select Sector SPDR ETF's stock fell -25.7% during the 2025 US Tariff Shock. Such a loss loss requires a 34.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Q/C Technologies (QCLS)
AI Analysis | Feedback
A clinical-stage AbbVie focused on next-generation inflammation treatments, with an added interest in advanced CBD therapeutics.
Imagine GW Pharmaceuticals (maker of Epidiolex) if it also developed novel drugs for chronic inflammation.
AI Analysis | Feedback
- MYMD-1: A drug platform designed to regulate the immune system to treat diseases and disorders marked by acute or chronic inflammation.
- Supera-CBD: A novel synthetic derivative of cannabidiol (CBD) being developed to treat chronic pain, addiction, and epilepsy.
AI Analysis | Feedback
TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.), which trades under the symbol QCLS, is a clinical-stage pharmaceutical company. This means it is currently focused on the research, development, and clinical trials of its drug platforms, MYMD-1 and Supera-CBD, rather than on the commercial sale of approved products.
As a clinical-stage company, TNF Pharmaceuticals, Inc. does not currently have major commercial customers (either other companies or individual consumers) from the sale of its therapeutic products. Its primary activities involve advancing its drug candidates through various phases of clinical development and seeking regulatory approvals.
AI Analysis | Feedback
nullAI Analysis | Feedback
Joshua Silverman, Executive Chairman and Principal Executive Officer
Joshua Silverman serves as the Executive Chairman and Principal Executive Officer of Q/C Technologies, Inc.. He previously held the position of Chairman of the Board for MyMD Pharmaceuticals, Inc., the company's predecessor, having joined its board in September 2018. Silverman is an experienced investment banker and management consultant. He co-founded and served as co-chief investment officer of Iroquois Capital Management, LLC, an investment advisory firm, from 2003 to 2016. Prior to that, he was co-chief investment officer of Vertical Ventures, LLC, a merchant bank, from 2000 to 2003. He has served on the boards of directors for several public companies, including AYRO, Inc., Protagenic Therapeutics, Neurotrope, Inc., Petros Pharmaceuticals, Inc., and Synaptogenix, Inc.. Earlier in his career, Silverman was a Director at Joele Frank, a firm specializing in mergers and acquisitions, and also served as Assistant Press Secretary to the President of the United States. He is currently also the interim Chief Executive Officer, President, and Director of PharmaCyte Biotech.
Ian Rhodes, Interim Chief Financial Officer
Ian Rhodes is the Interim Chief Financial Officer of Q/C Technologies, Inc.. He was initially appointed as Interim Chief Financial Officer for MyMD Pharmaceuticals, Inc. on February 1, 2021, and has continued in this role through the company's transitions. Rhodes began his career at PricewaterhouseCoopers, where he worked for 15 years. His prior experience includes serving as Interim CFO for Roadway Moving and Storage from March 2020 to December 2020, and for Greyston Bakery and Foundation from November 2018 to July 2019. He also held the positions of President, CEO, and Director of GlyEco, Inc. from December 2016 to September 2018, having previously served as its CFO from February 2016 to December 2016. From May 2014 to January 2016, he was the CFO of Calmare Therapeutics. Rhodes is a licensed CPA in New York and holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall University.
Mitchell Glass, M.D., Chief Medical Officer
Mitchell Glass, M.D., serves as the Chief Medical Officer of Q/C Technologies, Inc.. He was appointed President and Chief Medical Officer of MyMD Pharmaceuticals, Inc., the company's predecessor, in June 2024, and was also a member of its board of directors. Dr. Glass brings over 35 years of experience in the life sciences sector, with a track record of multiple drug approvals including Accolate®, Avandia®, and Coreg®. His extensive background includes guiding companies through regulatory processes, with 5 New Drug Applications (NDAs), 7 pre-NDA meetings, 12 End of Phase 2 (EOP2) meetings with the FDA, and more than 80 Investigational New Drug (IND) applications. Dr. Glass is board-certified in internal medicine, pulmonary, and critical care medicine, with a specialized focus on inflammatory diseases and immunopathology. His career spans various executive roles at major pharmaceutical companies, as well as founding, leading, and funding start-up and early-stage biopharma ventures. He is a founder and principal of Medpro Investors, a New York-based venture capital firm focused on the healthcare sector. Prior to his tenure at the Science Center, Dr. Glass held positions as Chief Medical Officer for AtheroGenics, Inc., and Vice President and Director of Cardiopulmonary Clinical Research, Development, and Medical Affairs at SmithKline Beecham.
AI Analysis | Feedback
Q/C Technologies (symbol: QCLS) faces key risks primarily due to its strategic pivot to a new technology sector, alongside the inherent challenges of its legacy pharmaceutical development. Here are the key risks to the business:- Market Volatility and Technological Uncertainty in Quantum-Class Computing and Blockchain: Q/C Technologies has explicitly shifted its strategic focus to developing quantum-class photonic computing for cryptocurrency and blockchain applications. This market is highly speculative, characterized by extreme volatility in asset prices, rapid technological changes, intense competition, and an uncertain regulatory landscape. The successful commercialization and widespread adoption of their technology in this nascent and rapidly evolving field are subject to significant uncertainty.
- High Failure Rate and Regulatory Hurdles in Clinical-Stage Pharmaceutical Development: Despite the strategic pivot, Q/C Technologies (formerly TNF Pharmaceuticals) continues to possess a pipeline of clinical-stage drug candidates, including MYMD-1 and Supera-CBD, as outlined in the background. Pharmaceutical development, particularly at the clinical stage, inherently carries a very high risk of failure during trials. Even if trials are successful, drugs face stringent, lengthy, and costly regulatory approval processes, with no guarantee of market authorization.
- Execution Risk of a Dual Business Model and Strategic Pivot: The company's recent and significant strategic pivot from a purely pharmaceutical focus to one emphasizing advanced computing for blockchain, potentially while still advancing pharmaceutical assets, presents substantial execution risks. Effectively managing two distinct and complex business models, requiring disparate expertise and significant resource allocation, could strain the company's financial, operational, and managerial capabilities, potentially hindering the success of both ventures.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Q/C Technologies (symbol: QCLS) has undergone a significant strategic pivot, changing its name from TNF Pharmaceuticals, Inc. in September 2025 to focus on quantum-class, high-performance computing infrastructure. The company's future revenue growth over the next 2-3 years is expected to be driven by the following factors: * Increased Adoption of Quantum-Class Laser Processing Units (LPUs): Q/C Technologies' revenue growth is anticipated to be driven by the sales and licensing of its proprietary qc-LPU100™ brand of quantum-class laser processing units. These units, which leverage light-based computing to solve complex problems at high speeds, are central to the company's new business model. * Expansion within the Cryptocurrency and Blockchain Infrastructure Market: The company has a stated focus on providing energy-efficient blockchain infrastructure. As the cryptocurrency and blockchain sectors continue to evolve and demand for more efficient and faster computing solutions grows, Q/C Technologies is positioned to capitalize on this need. * New Strategic Partnerships and Licensing Agreements: Q/C Technologies operates through a licensing agreement with LightSolver for its LPU technology. Future revenue growth can be expected from additional strategic alliances or licensing deals that expand the reach or application of its quantum-class computing solutions across various industries. * Advancements in Photonic Computing Technology: Continuous innovation and performance enhancements in its laser-based processing units could lead to wider adoption and new applications for Q/C Technologies' technology. The company emphasizes the potential for these LPUs to significantly reduce energy consumption while outperforming traditional computing methods. * Demand for Energy-Efficient High-Performance Computing: While initially focused on cryptocurrency, the underlying technology of quantum-class LPUs, with its emphasis on speed and energy efficiency, could address a broader market for high-performance computing needs across various compute-intensive industries.AI Analysis | Feedback
nullResearch & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.10 |
| Mkt Cap | 5.8 |
| Rev LTM | 527 |
| Op Inc LTM | -8 |
| FCF LTM | 15 |
| FCF 3Y Avg | 11 |
| CFO LTM | 28 |
| CFO 3Y Avg | 36 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 17.1% |
| Rev Chg 3Y Avg | 17.9% |
| Rev Chg Q | 16.6% |
| QoQ Delta Rev Chg LTM | 3.6% |
| Op Inc Chg LTM | 7.4% |
| Op Inc Chg 3Y Avg | 9.6% |
| Op Mgn LTM | -29.2% |
| Op Mgn 3Y Avg | -3.7% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 6.0% |
| CFO/Rev 3Y Avg | 16.5% |
| FCF/Rev LTM | 3.5% |
| FCF/Rev 3Y Avg | 13.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.8 |
| P/S | 7.9 |
| P/Op Inc | -3.7 |
| P/EBIT | -3.7 |
| P/E | -2.8 |
| P/CFO | 33.0 |
| Total Yield | -5.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.9% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.9% |
| 3M Rtn | 17.6% |
| 6M Rtn | 4.5% |
| 12M Rtn | -11.6% |
| 3Y Rtn | -11.6% |
| 1M Excs Rtn | 4.7% |
| 3M Excs Rtn | 5.9% |
| 6M Excs Rtn | -4.1% |
| 12M Excs Rtn | -40.4% |
| 3Y Excs Rtn | -97.1% |
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/15/2026 | 10-K |
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 08/19/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/11/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
Insider Activity
Updated 5/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Voss, Chelsea Sierra | Roth IRA | Buy | 5142026 | 3.15 | 1,753 | 5,522 | 193,898 | Form |
Industry Resources
| Information Technology Resources |
| TechCrunch |
| Wired |
| CIO |
| MIT Technology Review |
| Gartner Insights |
| Ars Technica |
| Technology Hardware, Storage & Peripherals Resources |
| The Verge |
| TechRadar |
| Tom’s Hardware |
| PCMag |
| CNET |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.